Aytu BioScience, Inc. announced that effective April 15, 2019, the Board appointed Steven J. Boyd, age 38, to the Board to fill one of the two vacancies on the Board. Since July 2012 Mr. Boyd has served as the Chief Investment Officer of Armistice Capital, LLC, the investment manager of Armistice Capital Master Fund Ltd. Effective April 15, 2019, Mr. Gary Cantrell resigned from the Company's Audit Committee and as Chairman of the Compensation Committee. Mr. Cantrell will remain a member of the Compensation Committee. In addition, effective April 15, 2019, the Board appointed Mr. Michael Macaluso to the Company's Audit Committee and the Compensation Committee and appointed Mr. Macaluso as Chairman of the Compensation Committee.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
